LFMDHealthcare · Health Information ServicesThe 8 Wall Street analysts covering LifeMD, Inc. hold a median 12-month price target of $7.5 — +126.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores LifeMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (14): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +126.9% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.00 |
| 6 Aug 2026 | B. Riley Securities | Maintains | Buy | $10 → $8.00 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $10 → $9.00 |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2026 | BTIG | Reiterates | Buy | — |
| 16 Mar 2026 | Mizuho | Upgrade | Outperform | — |
| 12 Mar 2026 | Freedom Broker | Maintains | Buy | — |
| 12 Mar 2026 | Freedom Capital Markets | Maintains | Buy | $8.00 → $10 |
| 11 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Mar 2026 | BTIG | Reiterates | Buy | — |
| 24 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Nov 2025 | Keybanc | Maintains | Overweight | — |
| 19 Nov 2025 | Mizuho | Maintains | Neutral | — |
| 18 Nov 2025 | B. Riley Securities | Maintains | Buy | — |
| 18 Nov 2025 | BTIG | Maintains | Buy | — |
| 18 Nov 2025 | Lake Street | Maintains | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Aug 2025 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 74% of US stocks
Cheaper than 5% of US stocks
Cheaper than 81% of US stocks
Higher than 22% of US stocks
Higher than 18% of US stocks
Higher than 96% of US stocks
Higher than 23% of US stocks
Higher than 47% of US stocks
Higher than 3% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LifeMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
LifeMD, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the call. The transcript documents the company's earnings discussion for the second quarter of 2026.
Why it matters — A LifeMD watcher would use this transcript to review management's own commentary and Q2 2026 results directly from the source.
LifeMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million. Elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.
Why it matters — The adjusted EBITDA loss and margin pressure signal that LifeMD's growth investments and GLP-1 pricing strategy are weighing on near-term profitability despite revenue meeting guidance.
LifeMD, Inc. reported a second-quarter loss of $0.16 per share, which was narrower than the Zacks Consensus Estimate of a $0.20 loss but wider than the $0.06 loss posted a year ago, while revenue lagged expectations.
Why it matters — An LFMD watcher would care because the quarter's earnings came in better than analysts expected, though revenue missed estimates and losses widened year over year.
LifeMD reported second quarter 2026 revenue of $47.3 million, within its guidance range, and an adjusted EBITDA loss of approximately $3.5 million, which improved about 21% sequentially. A duplicate table was removed from the press release.
Why it matters — The results show revenue landing within the company's own forecast and a sequential improvement in adjusted EBITDA loss, giving LFMD watchers a quarterly financial checkpoint.
LifeMD, Inc. announced it will report its second quarter 2026 financial results after the close of U.S. financial markets on August 5, 2026, and will host a conference call at 4:30 p.m. Eastern time that same day.
Why it matters — LFMD watchers will learn the company's latest quarterly performance and forward outlook during the scheduled earnings release and conference call on August 5.
The 8 Wall Street analysts covering LifeMD, Inc. have a median 12-month price target of $7.5, with estimates ranging from $5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering LifeMD, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LifeMD, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, LifeMD, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +126.9% from the last close, and Ticker Nerd's factor model ranks LifeMD, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LifeMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $15 over the next 12 months.
LifeMD, Inc. returned -47.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
LifeMD Inc. is a direct-to-patient telehealth company that provides virtual primary care services and pharmacy solutions in the United States.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript". LifeMD, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the call. The transcript documents the company's earnings discussion for the second quarter of 2026.
LifeMD Inc. is a direct-to-patient telehealth company that provides virtual primary care services and pharmacy solutions in the United States. It connects consumers to healthcare professionals through a platform featuring clinician-centric electronic medical records, remote lab testing, digital prescriptions, audio/video consultations, and cloud pharmacy fulfillment. Key brands include RexMD for men's health conditions such as erectile dysfunction, premature ejaculation, and hair loss, and ShapiroMD for virtual treatments and prescription medications. The company offers weight management programs with access to GLP-1 medications like Wegovy and Ozempic through collaborations with pharmaceutical partners, alongside nutritional supplements and over-the-counter products. Following the divestiture of its WorkSimpli software segment, LifeMD Inc. operates as a pure-play virtual care and pharmacy platform, emphasizing telehealth services that deliver convenient, cost-effective healthcare access. Headquartered in New York, NY, it leverages expertise in medicine, technology, marketing, and operations to serve patients seeking on-demand care.
CEO Mr. Justin Schreiber · 347 employees · United States · https://lifemd.com